{"schema_version":"secwatch.filing_event.v1","accession":"0001671927-26-000026","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2026-09-14T11:15:04+00:00","discovered_at":"2026-09-14T11:20:01.682430+00:00","generated_at":"2026-09-14T11:21:34.098827+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunocore achieves 540-patient target enrollment in Phase 3 TEBE-AM trial of tebentafusp in post-PD1 melanoma","bullets":["TEBE-AM enrolled 540 patients; randomized Phase 3 trial of tebentafusp ± pembrolizumab vs investigator's choice in HLA-A*02:01+ advanced melanoma.","Primary endpoint overall survival; topline data expected as early as end of 2026.","Trial targets previously treated post-PD1 advanced melanoma; potential addressable population ~4,000 patients in US/EU.","Registrational trial; enrollment milestone supports KIMMTRAK expansion beyond first-line uveal melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001671927-26-000026","json":"https://secwatch.observer/filing/0001671927-26-000026.json","markdown":"https://secwatch.observer/filing/0001671927-26-000026.md","text":"https://secwatch.observer/filing/0001671927-26-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/0001671927-26-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/imcr-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T11:21:34.098827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}